GlassScriptPhysician profile
Michael S Alexander
NPI 1407932288
$1,867.02
in general payments reported to CMS, 2019-2025
13 companies · $278 in 2025
The $278 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $441 · 2020: $151 · 2021: $307 · 2022: $323 · 2023: $181 · 2024: $187 · 2025: $278.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $598 · Entertainment: $28.95 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $598.40 |
| Entertainment | $28.95 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $520.63 | 2019-2025 | Acuvue |
| Bausch & Lomb Americas INC. | $255.99 | 2022-2024 | Infuse, Miebo |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $237.97 | 2019-2021 | |
| Coopervision INC. | $235.40 | 2019-2025 | Biofinity Contact Lens |
| Alcon Vision LLC | $220.49 | 2019-2025 | Total30, Dailies Total1 |
| Kala Pharmaceuticals, INC. | $120.79 | 2021 | |
| Maculogix, INC. | $62.57 | 2019 | |
| Optos, INC. | $57.97 | 2021-2024 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Lombart Brothers, INC. | $48.55 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $46.19 | 2024-2025 | |
| Allergan, INC. | $25.39 | 2021 | |
| Oyster Point Pharma, INC. | $17.77 | 2025 | Tyrvaya |
| Biotissue Holdings INC. | $17.31 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Alexander listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.